Abstract A 78-year-old Caucasian male with a history of atrial fibrillation and anticoagulation with warfarin presented with a change in bowel habits and weight loss. A computed tomography (CT) scan showed a 3.5 cm rectal mass. After biopsy with colonoscopy and endoscopic ultrasonography, the rectal mass was highly suspicious for rectal hematoma. When the rectal mass did not resolve after 1 month of follow-up, surgery showed the patient to have a rectal gastrointestinal stromal tumor. He is being treated with imatinib and follow-up CT scans. This case illustrates the importance of a high level of suspicion for a gastrointestinal stromal tumor when a rectal mass is found.
A 78-year-old Caucasian male with a history of atrial fibrillation on anticoagulation with warfarin was referred to our gastroenterology department for change in bowel habits, 20 lb of weight loss, and concern for a 3.5 cm rectal mass with inhomogeneous enhancement and bulging into the right lateral rectal wall noted on computed tomography (CT; Fig. 1 ).
The patient denied fever, chills, nausea, vomiting, melena, or abdominal pain. In anticipation of colonoscopy, his warfarin had been discontinued. A 4-cm firm fungating sessile mass was seen extending to the anal verge (Fig. 2 ). Biopsies were obtained and the patient was advised to resume anticoagulation 2 days after colonoscopy. The initial biopsy revealed multiple fragments of colonic mucosa with focal hyperplasia.
Three days later, the patient presented with the complaint of bright red blood per rectum with seven episodes in the previous 12 h. After initial resuscitation, a flexible sigmoidoscopy was performed and a large blood clot with active bleeding was revealed (Fig. 3) . Hemostasis was achieved with epinephrine injection therapy (1:10,000) and heater probe application.
A subsequent endoscopic ultrasound revealed a rectal mass suggestive of an abscess or organized hematoma (Fig. 4) . The preliminary fine needle aspiration (FNA) biopsy found only necrotic material; later, upon further review, the biopsy reported active colitis and surface erosion but was negative for malignancy. At that time, the working diagnosis was a rectal hematoma. The patient's warfarin was discontinued and he was followed up with a CT scan 1 month later. This CT did not demonstrate improvement in the hematoma. He was referred to the general surgery department for abdominoperoneal resection of a 6 cm rectal mass. The pathology report showed a gastrointestinal stromal tumor (GIST) with negative margins. Pathology was positive for c-kit (CD117) and CD34 stains. No reactivity was seen with antibodies to desmin, smooth muscle myosin, or S-100. Twenty-seven perirectal lymph nodes were identified histologically but showed no evidence of metastasis. The patient is being treated with imatinib 400 mg orally daily for at least 12 months.
Discussion
Gastrointestinal stromal tumor is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000. Despite being the most common nonepithelial benign neoplasm involving the gastrointestinal tract, mesenchymal tumors may constitute only 1% of primary gastrointestinal cancers [1, 2] . Benign GISTs are more common, but many tumors are of uncertain malignant potential. However, their true frequency is unknown. The rectum is the third most common site [3] .
Some GISTs are asymptomatic and discovered incidentally during an endoscopic or barium study or on a CT scan done for another purpose. More often, they are associated with nonspecific symptoms including early satiety, bloating, or weight loss; they can ulcerate, bleed, or grow large enough to cause pain or obstruction. GISTs have the potential to metastasize. GISTs frequently metastasize to the liver and peritoneum. They infrequently metastasize to the lungs and regional lymph nodes.
GISTs are related to the interstitial cells of Cajal. By light microscopy alone, the distinction among GISTs and other tumors in the differential diagnosis can be difficult. GIST cells have ability of overexpression of the transmembrane tyrosine kinase receptor c-kit. About 90% of GIST cases have a patognomonic mutation of the proto-oncogene c-kit (CD 117). Exon 11 is affected most frequently; exons 9 and 13 are less commonly involved. GISTs stain strongly for c-kit and/or CD34 and variably for actin but are almost always negative for desmin and S-100 protein, in contrast to other mesenchymal tumors [3] . Tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior [4] .
A thorough history and physical examination, including family history of GISTs, are important. CT scan/MRI of the abdomen and pelvis, chest imaging to rule out metastasis, Fig. 4 Endoscopic ultrasound of the rectal mass which suggested an abscess or organized hematoma and endoscopic ultrasonographic (EUS) are the investigative modalities. EUS may be helpful for distinguishing tumors that disrupt the normal tissue planes, contain cystic spaces, and are associated with enlarged lymph nodes from those that are more likely to be malignant. Benign tumors are more likely to have regular margins, a tumor size of ≤30 mm, and a homogeneous echo pattern [5] . The combined use of cytologic analysis, immunohistochemistry, and reverse transcriptase polymerase chain reaction for KIT mutations may permit the diagnosis of some of these lesions by EUSguided FNA [6, 7] . Tissue rather than cytologic study may be required for a definitive diagnosis.
Surgery is the treatment of choice for resectable nonmetastatic rectal GIST. Since skip metastases have never been reported, a wide resection is not required [3] . Segmental colectomy with negative margins is recommended and local excision is oncologically adequate in highly selected rectal tumors. Small rectal GIST (under 3 cm) with a limited extrarectal component can be treated by local excision as long as clear margins are achieved. Large tumors require resectional surgery, occasionally pelvic exenteration, to obtain R0 resections. Radical surgery alone is not always curative especially in high-risk GISTs, and half of patients developing local recurrences or distant metastases after R0 operation. As many as 38% of patients with rectal GIST are at risk of incomplete resection despite extensive procedures [3, 8] .
Targeted molecular therapy has led to a revolution in the chemotherapy. Conventional chemotherapy agents and radiation therapy have been ineffective treatment modalities [9] . Since 2002, imatinib mesylate has been extensively used for the treatment of metastatic and unresectable GIST at the dose of 400-600 mg/day. Imatinib mesylate, an adenosine triphosphate analog, is a specific tyrosine kinase receptor inhibitor and is effective in selectively blocking the aggressive and uncontrolled activity of c-kit in GIST cells, leading to an arrest in proliferation and apoptotic cell death. Distinct mutations may also predict response to therapy. Mutations involving exon 11 correlate with a higher in vitro and in vivo sensitivity to imatinib. Moreover, exon 11 kit mutations were associated with longer overall survival [10] . Unfortunately, patients on imatinib can develop secondary resistance related to additional c-kit mutations, while about 14% of patients are nonresponders and 5% complains of unacceptable side effects. In January 2006, the FDA approved sunitinib, which is in the same drug class. Schlemmer et al. have also reported the feasibility of nilotinib (400 mg bid) for the first-line treatment of metastatic GIST [11] .
Adjuvant use and neoadjuvant use of imatinib are promising therapeutic options to improve the outcome of surgery to downstage unresectable lesions and to allow less extensive resections. Currently, neoadjuvant therapy remains an experimental approach to be performed within prospective clinical studies. There is no consensus on the indications, optimal dose, appropriate duration, and timing for surgery [3] .
Rectal hematoma, or intramural hematoma (IH), can clinically present as intestinal obstruction or change in bowel habits. As little as 30 ml of hematoma have been shown to cause symptomatic small bowel obstruction, but a greater amount of blood is needed to produce colonic obstruction, due to the colon's larger lumen. Our patient presented with a change in bowel habits and weight loss. "Spontaneous" IH can be related to either hematologic bleeding disorders or therapeutic pharmacologic anticoagulation [12] . Our suspicion of rectal hematoma became high after the two negative biopsies, gastrointestinal bleeding after biopsy, and the rectal endoscopic ultrasound showed the rectal mass, which suggested an abscess or organized hematoma. The biopsy result was unexpected and the patient was referred to the oncology department. He is currently being treated with a follow-up plan for a CT scan every 6 months for 3 years and then annually.
Conclusion
Diagnosing a rectal GIST can be challenging even with advanced technology. The physician should have a high index of suspicion for the diagnosis of a rectal GIST. A thorough history and physical examination, imagining modalities including CT and MRI, and an expert endoscopist are advised. A multidisciplinary approach including expertise in sarcoma once there is high suspicion or a biopsy-proven rectal GIST diagnosis is also recommended.
